US Blood Cancer Drug Market & Pipeline Analysis 2015

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Pharmaceutical companies have identified the opportunities to generate significant revenues from blood cancer segment in US. Escalating blood cancer incidences, high unmet medical necessities and demand for better therapeutics are some major factors behind growth of US blood cancer market segment. Higher investments have been made by pharmaceutical companies in order to come forth with better therapeutics for generating significant revenues. As a result, numerous therapeutic have been introduced in US market for the successful treatment of blood cancer. Several innovative therapeutics are at different stages of clinical trials which would be introduced in coming years.

Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs.

Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market.

Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase.

\"US Blood Cancer Drug Market & Pipeline Analysis 2015\" Report Highlights:

Blood Cancer Incidence & Prevalence
Blood Cancer Drug Market Overview
Blood Cancer Drug Market Dynamics
Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight
Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs
Majority Drugs in Phase-I Clinical Trials: 128 Drugs
Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis
Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs

1. US Blood Cancer Incidence & Prevalence

1.1 Leukemia: Cancer of White Blood Cells (WBC)

1.1.1 Acute Lymphocytic Leukemia (ALL)

1.1.2 Acute Myeloid Leukemia (AML)

1.1.3 Chronic Lymphocytic Leukemia (CLL)

1.1.4 Chronic Myeloid Leukemia (CML)

1.2 Lymphoma: Cancer of Lymphatic System

1.2.1 Hodgkin Lymphoma

1.2.2 Non-Hodgkin Lymphoma (NHL)

1.3 Myeloma

2. US Blood Cancer Drug Market Overview

2.1 Current Market Scenario

2.2 US Blood Cancer Drug Clinical Pipeline Overview

3. US Blood Cancer Drug Market Dynamics

3.1 Favorable Market Parameters

3.2 Commercialization Challenges

4. US Blood Cancer Drug Market Future Prospects

5. Mechanism of Blood Cancer Therapeutics

6. Leukemia Drug Clinical Pipeline by Company & Phase

6.1 Research till Registered

6.2 Discontinued & Suspended Leukemia Drug Clinical Insight

7. Marketed Leukemia Drug Clinical Insight

7.1 Alemtuzumab (Campath®)

7.2 Arsenic Trioxide (Trisenox®)

7.3 Bosutinib (Bosulif®)

7.4 Clofarabine

7.5 Crisantaspase (Erwinaze®)

7.6 Dasatinib (Sprycel®)

7.7 Fludarabine (Fludara®)

7.8 Idarubicin (Idamycin®)

7.9 Imatinib (Gleevec®)

7.10 Irinotecan

7.11 Mercaptopurine Oral Suspension (Purixan™)

7.12 Mitoxantrone (Novantrone®)

7.13 Nilotinib (Tasigna®)

7.14 Obinutuzumab (Gazyva®)

7.15 Ofatumumab (Arzerra®)

7.16 Omacetaxine Mepesuccinate (Synribo®)

7.17 Pegaspargase (Oncaspar®)

7.18 Pentostatin (Nipent®)

7.19 Ponatinib (Iclusig®)

7.20 Sargramostim (Leukine®)

7.21 Tretinoin

7.22 Vincristine Liposomal - Spectrum Pharmaceuticals (Marqibo®)

8. Lymphoma Drug Clinical Pipeline by Company & Phase

8.1 Research till Registered

8.2 Discontinued & Suspended Lymphoma Drug Clinical Insight

9. Marketed Lymphoma Drug Clinical Insight

9.1 Belinostat (Beleodaq®)

9.2 Bexarotene Oral (Targretin®)

9.3 Bexarotene Topical (Targretin®)

9.4 Brentuximab Vedotin (Adcetris®)

9.5 Chlormethine (Valchlor™)

9.6 Denileukin Diftitox (ONTAK®)

9.7 Ibritumomab Tiuxetan (Zevalin®)

9.8 Interferon Alpha-2b (Intron® A)

9.9 Pralatrexate (Folotyn®)

9.10 Romidepsin (Istodax®)

9.11 Vorinostat (Zolinza®)

10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase

10.1 Research till Preregistration

10.2 Discontinued & No Development Reported in Multiple Myeloma Drug Clinical Insight

11. Marketed Multiple Myeloma Drug Clinical Insight

11.1 Carfilzomib (Kyprolis®)

11.2 Doxorubicin Liposomal – ALZA

11.3 Pomalidomide (Pomalyst®)

11.4 Thalidomide (Thalomid®)

11.5 Zoledronic Acid (Zometa®)

12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase

12.1 Research till Preregistration

12.2 Discontinued & Suspended Multiple Blood Cancer Drug Clinical Insight

13. Marketed Multiple Blood Cancer Drug Clinical Insight

13.1 Azacitidine (Vidaza®)

13.2 Bendamustine (Treanda®)

13.3 Bortezomib (Velcade®)

13.4 Cladribine (Leustatin®)

13.5 Decitabine (Dacogen®)

13.6 Ibrutinib (Imbruvica®)

13.7 Idelalisib

13.8 Lenalidomide (Revlimid®)

13.9 Nelarabine (Arranon®)

13.10 Rituximab (Rituxan®)

14. Competitive Landscape

14.1 Actelion Pharmaceuticals

14.2 Amgen

14.3 ARIAD Pharmaceuticals

14.4 Astellas Pharma

14.5 Baxter BioScience

14.6 Bayer HealthCare Pharmaceuticals Inc.

14.7 Biogen Idec

14.8 Bristol-Myers Squibb

14.9 CASI Pharmaceuticals

14.10 Celera Genomics Group

14.11 Celgene Corporation

14.12 Eisai

14.13 Genmab

14.14 Gilead Sciences

14.15 GlaxoSmithKline

14.16 Hospira

14.17 Johnson & Johnson

14.18 Millennium Pharmaceuticals

14.19 Nova Laboratories

14.20 Novartis

14.21 Onxeo SA

14.22 Onyx Pharmaceuticals

14.23 Otsuka Pharmaceutical

14.24 Pfizer

14.25 Roche

14.26 Scripps Clinic

14.27 Seattle Genetics

14.28 SRI International

14.29 Southern Research Institute

14.30 Tekmira Pharmaceuticals Corporation

14.31 Teva Pharmaceutical Industries

14.32 Yakult Honsha

Figure 1-1: Main Types of Blood Cancer

Figure 1-2: Percentage of Leukemia in New Cancer Cases, 2015

Figure 1-3: Percentage of Leukemia in all Cancer Related Deaths, 2015

Figure 1-4: Leukemia Estimated Cases, 2013-2015

Figure 1-5: Leukemia Estimated New Cases in Males, 2013-2015

Figure 1-6: Leukemia Estimated New Cases in Females, 2013-2015

Figure 1-7: Leukemia Estimated Deaths, 2013-2015

Figure 1-8: Leukemia Estimated Deaths in Males, 2013-3015

Figure 1-9: Leukemia Estimated Deaths in Females, 2013-2015

Figure 1-10: Percentage of Acute Lymphocytic Leukemia in Cancer Related Deaths, 2015

Figure 1-11: Percentage of Acute Lymphocytic Leukemia in New Cancer Cases, 2015

Figure 1-12: Acute Lymphocytic Leukemia Estimated New Cases, 2013-2015

Figure 1-13: Acute Lymphocytic Leukemia Estimated New Cases in Males, 2013-2015

Figure 1-14: Acute Lymphocytic Leukemia Estimated New Cases in Female, 2013-2015

Figure 1-15: Acute Lymphocytic Leukemia Estimated Deaths, 2013-2015

Figure 1-16: Acute Lymphocytic Leukemia Estimated Deaths in Males, 2013-2015

Figure 1-17: Acute Lymphocytic Leukemia Estimated Deaths in Females, 2013-2015

Figure 1-18: Acute Myeloid Leukemia Estimated New Cases, 2013-2015

Figure 1-19: Acute Myeloid Leukemia Estimated New Cases in Males, 2013-2015

Figure 1-20: Acute Myeloid Leukemia Estimated New Cases in Females, 2013-2015

Figure 1-21: Percentage of Acute Myeloid Leukemia in New Cancer Cases, 2015

Figure 1-22: Percentage of Acute Myeloid Leukemia in all Cancer Deaths, 2015

Figure 1-23: Acute Myeloid Leukemia Estimated Deaths, 2013-2015

Figure 1-24: Acute Myeloid Leukemia Estimated Deaths in Male, 2013-2015

Figure 1-25: Acute Myeloid Leukemia Estimated Deaths in Female, 2013-2015

Figure 1-26: Chronic Lymphocytic Leukemia Estimated New Cases, 2013-2015

Figure 1-27: Chronic Lymphocytic Leukemia Estimated New Cases in Males, 2013-2015

Figure 1-28: Chronic Lymphocytic Leukemia Estimated New Cases in Females, 2013-2015

Figure 1-29: Chronic Lymphocytic Leukemia Estimated Deaths, 2013-2015

Figure 1-30: Percentage of Chronic Lymphocytic Leukemia in New Cancer Cases, 2015

Figure 1-31: Percentage of Chronic Lymphocytic Leukemia in all Cancer Related Deaths, 2015

Figure 1-32: Chronic Lymphocytic Leukemia Estimated Deaths in Males, 2013-2015

Figure 1-33: Chronic Lymphocytic Leukemia Estimated Deaths in Females, 2013-2015

Figure 1-34: Percentage of Chronic Myeloid Leukemia in New Cancer Cases, 2015

Figure 1-35: Percentage of Chronic Myeloid Leukemia in all Cancer Related Deaths, 2015

Figure 1-36: Categories of Chronic Myeloid Leukemia (CML)

Figure 1-37: Chronic Myeloid Leukemia Estimated New Cases, 2013-2015

Figure 1-38: Estimated New Cases of Chronic Myeloid Leukemia in Males, 2013-2015

Figure 1-39: Estimated New Cases of Chronic Myeloid Leukemia in Females, 2013-2015

Figure 1-40: Estimated Deaths due to Chronic Myeloid Leukemia, 2013-2015

Figure 1-41: Estimated Deaths due to Chronic Myeloid Leukemia in Male, 2013-2015

Figure 1-42: Estimated Deaths due to Chronic Myeloid Leukemia in Female, 2013-2015

Figure 1-43: Types of Lymphoma

Figure 1-44: Identification of Different Types of Lymphomas

Figure 1-45: Lymphoma Estimated New Cases, 2013-2015

Figure 1-46: Estimated New Cases of Lymphoma in Males, 2013-2015

Figure 1-47: Estimated New Cases of Lymphoma in Females, 2013-2015

Figure 1-48: Estimated Lymphoma Deaths, 2013-2015

Figure 1-49: Lymphoma Estimated Deaths in Males, 2013-2015

Figure 1-50: Lymphoma Estimated Deaths in Females, 2013-2015

Figure 1-51: Percentage of Hodgkin Lymphoma in New Cancer Cases, 2015

Figure 1-52: Percentage of Hodgkin Lymphoma in all Cancer Related Deaths, 2015

Figure 1-53: Estimated New Cases of Hodgkin Lymphoma, 2013-2015

Figure 1-54: Estimated New Cases of Hodgkin Lymphoma in Male, 2013-2015

Figure 1-55: Estimated New Cases of Hodgkin Lymphoma in Females, 2013-2015

Figure 1-56: Hodgkin Lymphoma Estimated Deaths, 2013-2015

Figure 1-57: Hodgkin Lymphoma Estimated Deaths in Males, 2013-2015

Figure 1-58: Hodgkin Lymphoma Estimated Deaths in Female, 2013-2015

Figure 1-59: Percentage of Non-Hodgkin Lymphoma (NHL) in New Cancer Cases, 2015

Figure 1-60: Percentage of Non-Hodgkin Lymphoma in all Cancer Related Deaths, 2015

Figure 1-61: Non-Hodgkin Lymphoma Estimated New Cases, 2013-2015

Figure 1-62: Non-Hodgkin Lymphoma Estimated New Cases in Male, 2013-2015

Figure 1-63: Non-Hodgkin Lymphoma Estimated New Cases in Female, 2013-2015

Figure 1-64: Non-Hodgkin Lymphoma Estimated Deaths, 2013-2015

Figure 1-65: Non-Hodgkin Lymphoma Estimated Deaths in Males, 2013-2015

Figure 1-66: Non-Hodgkin Lymphoma Estimated Deaths in Females, 2015- 2013

Figure 1-67: Percentage of Myeloma in New Cancer Cases, 2015

Figure 1-68: Myeloma Estimated New Cases, 2013-2015

Figure 1-69: Myeloma Estimated New Cases in Males, 2013-2105

Figure 1-70: Myeloma Estimated New Cases in Females, 2013-2015

Figure 1-71: Percentage of Myeloma in all Cancer Related Deaths, 2015

Figure 1-72: Myeloma Estimated Deaths, 2013-2015

Figure 1-73: Myeloma Estimated Deaths in Males, 213-2015

Figure 1-74: Myeloma Estimated Deaths in Females, 2013-2015

Figure 2-1: Blood Cancer Drug Pipeline Overview by Phase (%), 2015

Figure 2-2: Blood Cancer Drug Pipeline Overview by Phase (Number), 2015

Figure 2-3: No Development Reported Blood Cancer Drug Pipeline Overview by Phase (%), 2015

Figure 2-4: No Development Reported Blood Cancer Drug Pipeline Overview by Phase (Number), 2015

Figure 2-5: Discontinued Blood Cancer Drug Pipeline Overview by Phase (%), 2015

Figure 2-6: Discontinued Blood Cancer Drug Pipeline Overview by Phase (Number), 2015

Figure 2-7: Suspended Blood Cancer Drug Pipeline Overview by Phase (%), 2015

Figure 2-8: Suspended Blood Cancer Drug Pipeline Overview by Phase (Number), 2015

Figure 2-9: Leukemia Drug Pipeline Overview by Phase (%), 2015

Figure 2-10: Leukemia Drug Pipeline Overview by Phase (Number), 2015

Figure 2-11: No Development Reported Leukemia Drug Pipeline Overview by Phase (%), 2015

Figure 2-12: No Development Reported Leukemia Drug Pipeline Overview by Phase (Number), 2015

Figure 2-13: Discontinued Leukemia Drug Pipeline Overview by Phase (%), 2015

Figure 2-14: Discontinued Leukemia Drug Pipeline Overview by Phase (Number), 2015

Figure 2-15: Suspended Leukemia Drug Pipeline Overview by Phase (%), 2015

Figure 2-16: Suspended Leukemia Drug Pipeline Overview by Phase (Number), 2015

Figure 2-17: Lymphoma Drug Pipeline Overview by Phase (%), 2015

Figure 2-18: Lymphoma Drug Pipeline Overview by Phase (Number), 2015

Figure 2-19: No Development Reported Lymphoma Drug Pipeline Overview by Phase (%), 2015

Figure 2-20: No Development Reported Lymphoma Drug Pipeline Overview by Phase (Number), 2015

Figure 2-21: Discontinued Lymphoma Drug Pipeline Overview by Phase (%), 2015

Figure 2-22: Discontinued Lymphoma Drug Pipeline Overview by Phase (Number), 2015

Figure 2-23: Suspended Lymphoma Drug Pipeline Overview by Phase (%), 2015

Figure 2-24: Suspended Lymphoma Drug Pipeline Overview by Phase (Number), 2015

Figure 2-25: Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015

Figure 2-26: Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015

Figure 2-27: No Development Reported Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015

Figure 2-28: No Development Reported Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015

Figure 2-29: Discontinued Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015

Figure 2-30: Discontinued Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015

Figure 2-31: Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015

Figure 2-32: Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015

Figure 2-33: No Development Reported Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015

Figure 2-34: No Development Reported Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015

Figure 2-35: Discontinued Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015

Figure 2-36: Discontinued Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015

Figure 2-37: Suspended Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015

Figure 2-38: Suspended Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015

Figure 3-1: US Blood Cancer Drug Market Favorable Parameters

Figure 3-2: US Blood Cancer Drug Market Commercialization Challenges

Figure 5-1: Mechanism of Idelalisib

Figure 5-2: Mechanism of Imatinib

Figure 5-3: Mechanism of Rituximab

Figure 5-4: Mechanism of Doxorubicin

Figure 5-5: Mechanism of Carfilzomib

Figure 14-1: Actelion Pharmaceuticals Clinical Pipeline

Figure 14-2: Amgen Clinical Pipeline

Figure 14-3: ARIAD Clinical Pipeline

Figure 14-4: Casi Pharmaceutical Clinical Pipeline

Figure 14-5: Celgene Clinical Pipeline

Figure 14-6: Gilead Sciences Clinical Pipeline

Figure 14-7: GalaxoSmithKline Clinical Pipeline

Figure 14-8: Millennium Pharmaceuticals Clinical Pipeline

Figure 14-9: Novartis Clinical Pipeline

Figure 14-10: Onxeo SA Clinical Pipeline

Figure 14-11: Roche Clinical Pipeline

Figure 14-12: Tekmira Clinical Pipeline

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

US Blood Cancer Drug Market & Pipeline Analysis 2015

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected